Titre : Virus Junin

Virus Junin : Questions médicales fréquentes

Termes MeSH sélectionnés :

Prostatic Neoplasms
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Virus Junin : Questions médicales les plus fréquentes", "headline": "Virus Junin : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Virus Junin : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-01-21", "dateModified": "2025-04-15", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Virus Junin" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Arénavirus du Nouveau Monde", "url": "https://questionsmedicales.fr/mesh/D006477", "about": { "@type": "MedicalCondition", "name": "Arénavirus du Nouveau Monde", "code": { "@type": "MedicalCode", "code": "D006477", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "B04.820.480.500.070.095" } } }, "about": { "@type": "MedicalCondition", "name": "Virus Junin", "alternateName": "Junin virus", "code": { "@type": "MedicalCode", "code": "D018051", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Cheng Huang", "url": "https://questionsmedicales.fr/author/Cheng%20Huang", "affiliation": { "@type": "Organization", "name": "Department of Pathology, University of Texas Medical Branch, Galveston, Texas, United States of America." } }, { "@type": "Person", "name": "Slobodan Paessler", "url": "https://questionsmedicales.fr/author/Slobodan%20Paessler", "affiliation": { "@type": "Organization", "name": "Department of Pathology, University of Texas Medical Branch, Galveston, Texas, United States of America." } }, { "@type": "Person", "name": "Duncan R Smith", "url": "https://questionsmedicales.fr/author/Duncan%20R%20Smith", "affiliation": { "@type": "Organization", "name": "Institute of Molecular Biosciences, Mahidol University, Salaya, 73170, Thailand. duncan_r_smith@hotmail.com." } }, { "@type": "Person", "name": "Vahid Rajabali Zadeh", "url": "https://questionsmedicales.fr/author/Vahid%20Rajabali%20Zadeh", "affiliation": { "@type": "Organization", "name": "Department of Emerging Infectious Diseases, Institute of Tropical Medicine (NEKKEN), Nagasaki University, Nagasaki, Japan." } }, { "@type": "Person", "name": "Shuzo Urata", "url": "https://questionsmedicales.fr/author/Shuzo%20Urata", "affiliation": { "@type": "Organization", "name": "Department of Emerging Infectious Diseases, National Research Center for the Control and Prevention of Infectious Diseases (CCPID), Nagasaki University, Nagasaki, Japan." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Identification macrophage signatures in prostate cancer by single-cell sequencing and machine learning.", "datePublished": "2024-02-13", "url": "https://questionsmedicales.fr/article/38349474", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1007/s00262-024-03633-5" } }, { "@type": "ScholarlyArticle", "name": "The value of PROMs for predicting erectile dysfunction in prostate cancer patients with Bayesian network.", "datePublished": "2024-02-13", "url": "https://questionsmedicales.fr/article/39188594", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.tipsro.2024.100234" } }, { "@type": "ScholarlyArticle", "name": "MRI-based prostate cancer classification using 3D efficient capsule network.", "datePublished": "2024-02-12", "url": "https://questionsmedicales.fr/article/38346111", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1002/mp.16975" } }, { "@type": "ScholarlyArticle", "name": "Developing Folate-Conjugated miR-34a Therapeutic for Prostate Cancer: Challenges and Promises.", "datePublished": "2024-02-09", "url": "https://questionsmedicales.fr/article/38396800", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3390/ijms25042123" } }, { "@type": "ScholarlyArticle", "name": "Clinical application of machine learning models in patients with prostate cancer before prostatectomy.", "datePublished": "2024-02-08", "url": "https://questionsmedicales.fr/article/38331808", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1186/s40644-024-00666-y" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Virus", "item": "https://questionsmedicales.fr/mesh/D014780" }, { "@type": "ListItem", "position": 3, "name": "Virus à ARN", "item": "https://questionsmedicales.fr/mesh/D012328" }, { "@type": "ListItem", "position": 4, "name": "Virus à ARN de polarité négative", "item": "https://questionsmedicales.fr/mesh/D000086103" }, { "@type": "ListItem", "position": 5, "name": "Arenaviridae", "item": "https://questionsmedicales.fr/mesh/D001116" }, { "@type": "ListItem", "position": 6, "name": "Arenavirus", "item": "https://questionsmedicales.fr/mesh/D018050" }, { "@type": "ListItem", "position": 7, "name": "Arénavirus du Nouveau Monde", "item": "https://questionsmedicales.fr/mesh/D006477" }, { "@type": "ListItem", "position": 8, "name": "Virus Junin", "item": "https://questionsmedicales.fr/mesh/D018051" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Virus Junin - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Virus Junin", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-13", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Virus Junin", "description": "Comment diagnostique-t-on l'infection par le virus Junin ?\nQuels tests sont utilisés pour confirmer le virus Junin ?\nLes symptômes aident-ils au diagnostic du virus Junin ?\nPeut-on diagnostiquer le virus Junin par culture virale ?\nLe diagnostic précoce est-il important pour le virus Junin ?", "url": "https://questionsmedicales.fr/mesh/D018051?mesh_terms=Prostatic+Neoplasms&page=1000#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Virus Junin", "description": "Quels sont les symptômes de l'infection par le virus Junin ?\nLa fièvre est-elle un symptôme courant du virus Junin ?\nLes symptômes du virus Junin peuvent-ils varier ?\nY a-t-il des symptômes neurologiques associés au virus Junin ?\nLes symptômes apparaissent-ils rapidement après l'infection ?", "url": "https://questionsmedicales.fr/mesh/D018051?mesh_terms=Prostatic+Neoplasms&page=1000#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Virus Junin", "description": "Comment prévenir l'infection par le virus Junin ?\nLa vaccination contre le virus Junin est-elle disponible ?\nQuelles mesures d'hygiène sont recommandées ?\nLes rongeurs sont-ils un vecteur de transmission ?\nLes voyageurs doivent-ils se vacciner contre le virus Junin ?", "url": "https://questionsmedicales.fr/mesh/D018051?mesh_terms=Prostatic+Neoplasms&page=1000#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Virus Junin", "description": "Quel est le traitement principal pour l'infection par le virus Junin ?\nDes antiviraux sont-ils efficaces contre le virus Junin ?\nLa transfusion sanguine est-elle utilisée dans le traitement ?\nLe traitement précoce améliore-t-il le pronostic ?\nY a-t-il des traitements expérimentaux pour le virus Junin ?", "url": "https://questionsmedicales.fr/mesh/D018051?mesh_terms=Prostatic+Neoplasms&page=1000#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Virus Junin", "description": "Quelles sont les complications possibles de l'infection par le virus Junin ?\nLes complications surviennent-elles souvent ?\nLe virus Junin peut-il causer des séquelles à long terme ?\nLes complications sont-elles plus fréquentes chez certains groupes ?\nComment gérer les complications du virus Junin ?", "url": "https://questionsmedicales.fr/mesh/D018051?mesh_terms=Prostatic+Neoplasms&page=1000#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Virus Junin", "description": "Quels sont les principaux facteurs de risque pour le virus Junin ?\nLes agriculteurs sont-ils à risque d'infection par le virus Junin ?\nLes personnes immunodéprimées sont-elles plus vulnérables ?\nLe sexe influence-t-il le risque d'infection par le virus Junin ?\nLes personnes vivant en milieu urbain sont-elles à risque ?", "url": "https://questionsmedicales.fr/mesh/D018051?mesh_terms=Prostatic+Neoplasms&page=1000#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostique-t-on l'infection par le virus Junin ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Le diagnostic repose sur des tests sérologiques et PCR pour détecter le virus." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour confirmer le virus Junin ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Les tests ELISA et la PCR sont couramment utilisés pour confirmer l'infection." } }, { "@type": "Question", "name": "Les symptômes aident-ils au diagnostic du virus Junin ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les symptômes cliniques orientent le diagnostic, mais des tests sont nécessaires." } }, { "@type": "Question", "name": "Peut-on diagnostiquer le virus Junin par culture virale ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "La culture virale est possible mais moins courante en raison des risques de contagion." } }, { "@type": "Question", "name": "Le diagnostic précoce est-il important pour le virus Junin ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Oui, un diagnostic précoce permet une prise en charge rapide et améliore le pronostic." } }, { "@type": "Question", "name": "Quels sont les symptômes de l'infection par le virus Junin ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes incluent fièvre, myalgies, fatigue, et parfois des hémorragies." } }, { "@type": "Question", "name": "La fièvre est-elle un symptôme courant du virus Junin ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Oui, la fièvre est l'un des symptômes les plus fréquents de l'infection." } }, { "@type": "Question", "name": "Les symptômes du virus Junin peuvent-ils varier ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'intensité et la nature des symptômes peuvent varier d'une personne à l'autre." } }, { "@type": "Question", "name": "Y a-t-il des symptômes neurologiques associés au virus Junin ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Des symptômes neurologiques peuvent survenir, notamment des troubles de la conscience." } }, { "@type": "Question", "name": "Les symptômes apparaissent-ils rapidement après l'infection ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes apparaissent généralement 1 à 3 semaines après l'exposition au virus." } }, { "@type": "Question", "name": "Comment prévenir l'infection par le virus Junin ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "La prévention passe par l'évitement des contacts avec les rongeurs et la vaccination." } }, { "@type": "Question", "name": "La vaccination contre le virus Junin est-elle disponible ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Oui, une vaccination est disponible et recommandée pour les populations à risque." } }, { "@type": "Question", "name": "Quelles mesures d'hygiène sont recommandées ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Des mesures d'hygiène strictes, comme le nettoyage des lieux infestés, sont essentielles." } }, { "@type": "Question", "name": "Les rongeurs sont-ils un vecteur de transmission ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les rongeurs sont les principaux réservoirs et vecteurs du virus Junin." } }, { "@type": "Question", "name": "Les voyageurs doivent-ils se vacciner contre le virus Junin ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les voyageurs se rendant dans des zones endémiques doivent envisager la vaccination." } }, { "@type": "Question", "name": "Quel est le traitement principal pour l'infection par le virus Junin ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Le traitement est principalement symptomatique, avec des soins de soutien en cas de gravité." } }, { "@type": "Question", "name": "Des antiviraux sont-ils efficaces contre le virus Junin ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Actuellement, il n'existe pas d'antiviraux spécifiques approuvés pour le virus Junin." } }, { "@type": "Question", "name": "La transfusion sanguine est-elle utilisée dans le traitement ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Des transfusions peuvent être nécessaires en cas de complications hémorragiques sévères." } }, { "@type": "Question", "name": "Le traitement précoce améliore-t-il le pronostic ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Oui, un traitement précoce et approprié peut améliorer le pronostic des patients." } }, { "@type": "Question", "name": "Y a-t-il des traitements expérimentaux pour le virus Junin ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Des recherches sont en cours sur des traitements expérimentaux, mais rien n'est encore validé." } }, { "@type": "Question", "name": "Quelles sont les complications possibles de l'infection par le virus Junin ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Les complications peuvent inclure des hémorragies, des troubles neurologiques et la mort." } }, { "@type": "Question", "name": "Les complications surviennent-elles souvent ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Les complications graves sont rares mais peuvent survenir chez certains patients." } }, { "@type": "Question", "name": "Le virus Junin peut-il causer des séquelles à long terme ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des séquelles neurologiques peuvent persister après la guérison de l'infection." } }, { "@type": "Question", "name": "Les complications sont-elles plus fréquentes chez certains groupes ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les personnes immunodéprimées sont plus à risque de complications sévères." } }, { "@type": "Question", "name": "Comment gérer les complications du virus Junin ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "La gestion des complications nécessite des soins médicaux intensifs et un suivi approprié." } }, { "@type": "Question", "name": "Quels sont les principaux facteurs de risque pour le virus Junin ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les facteurs incluent l'exposition aux rongeurs et le travail en zones endémiques." } }, { "@type": "Question", "name": "Les agriculteurs sont-ils à risque d'infection par le virus Junin ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les agriculteurs travaillant dans des zones infestées par des rongeurs sont à risque." } }, { "@type": "Question", "name": "Les personnes immunodéprimées sont-elles plus vulnérables ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elles présentent un risque accru de développer des formes graves de la maladie." } }, { "@type": "Question", "name": "Le sexe influence-t-il le risque d'infection par le virus Junin ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Des études montrent que le risque peut varier selon le sexe, mais les raisons ne sont pas claires." } }, { "@type": "Question", "name": "Les personnes vivant en milieu urbain sont-elles à risque ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Le risque est généralement plus faible en milieu urbain, mais des cas sporadiques peuvent survenir." } } ] } ] }

Sources (10000 au total)

Identification macrophage signatures in prostate cancer by single-cell sequencing and machine learning.

The tumor microenvironment (TME) encompasses a variety of cells that influence immune responses and tumor growth, with tumor-associated macrophages (TAM) being a crucial component of the TME. TAM can ... First, we downloaded prostate cancer single-cell sequencing data and second-generation sequencing data from multiple public databases. From these data, we identified characteristic genes associated wi... In this study, the TAM_2 cell cluster has been identified as promoting the progression of prostate cancer, possibly representing M2 macrophages. The 9 TAM feature genes selected through ten machine le... This study has analyzed the potential relationship between TAM and PCa and established a TAM-related prognostic model. It holds promise as a valuable tool for the management and treatment of PCa patie...

The value of PROMs for predicting erectile dysfunction in prostate cancer patients with Bayesian network.

This study aims to develop and externally validate a clinically plausible Bayesian network structure to predict one-year erectile dysfunction in prostate cancer patients by combining expert knowledge ... For men with localized prostate cancer, choosing the optimal treatment can be challenging since each option comes with different side effects, such as erectile dysfunction, which negatively impacts th... 946 prostate cancer patients from 65 Dutch hospitals were considered to develop the Bayesian network structure. Continuous variables were discretized before analysis based on expert opinions and liter... BMI and prostate volume via MRI were excluded from this analysis due to their high percentage of missingness (... Bayesian network structures derived from PROM information by complimenting expert knowledge with evidence from the data produce a clinically plausible structure that is more performant than structures...

MRI-based prostate cancer classification using 3D efficient capsule network.

Prostate cancer (PCa) is the most common cancer in men and the second leading cause of male cancer-related death. Gleason score (GS) is the primary driver of PCa risk-stratification and medical decisi... Computer-aided diagnosis employing quantitative MRI analysis has yielded promising results in non-invasive prediction of GS. However, convolutional neural networks (CNNs) do not implicitly impose a fr... In our method, we used 3D CNN modules to extract spatial features and primary capsule layers to encode vector features. We then propose to integrate fully-connected capsule layers (FC Caps) to create ... Two groups of experiments were performed: (1) we first identified high-risk disease by classifying low + medium risk versus high risk; (2) we then stratified disease in one-versus-one fashion: low ver... In this study, we proposed a novel 3D Efficient CapsNet for PCa risk stratification and demonstrated its feasibility. This developed tool provided a non-invasive approach to assess PCa risk from T2W M...

Clinical application of machine learning models in patients with prostate cancer before prostatectomy.

To build machine learning predictive models for surgical risk assessment of extracapsular extension (ECE) in patients with prostate cancer (PCa) before radical prostatectomy; and to compare the use of... This retrospective observational study included two independent data sets: 139 participants from a single institution (training), and 55 from 15 other institutions (external validation), both treated ... In the training data, the model using clinical, semantic, and radiomics features gave the highest net benefit values across relevant threshold probabilities, and similar decision curve was observed in... The combined model based on clinical, semantic and radiomic features may be used to predict pECE + in patients with PCa and results in a positive net benefit when used to choose between prostatectomy ...

Impact of Prostate Size on the Functional and Oncological Outcomes of Robot-assisted Radical Prostatectomy.

Robot-assisted radical prostatectomy (RARP) is the main surgical approach for treatment of prostate cancer in the USA. Prostate size is always depicted as a factor affecting the outcomes of RARP as sh... A cohort of 14 481 patients who underwent RARP in a single center was divided into four groups according to prostate specimen weight: group 1, <50 g; group 2, 50-100 g; group 3, 100-150 g; and group 4... Patients with larger prostates (groups 3 and 4) were more likely to have higher prostate-specific antigen (PSA), lower biopsy grade group, and worse baseline urinary and sexual characteristics. Group ... The results demonstrate that in this large cohort of patients, greater prostate size affects multiple outcomes, including the rate of nerve-sparing surgery, potency and continence recovery, and oncolo... Our study shows that prostate size can affect the outcomes of robot-assisted removal of the prostate for patients with prostate cancer. Larger prostate size can be associated with worse functional out...

Focal radiotherapy boost to MR-visible tumor for prostate cancer: a systematic review.

The FLAME trial provides strong evidence that MR-guided external beam radiation therapy (EBRT) focal boost for localized prostate cancer increases biochemical disease-free survival (bDFS) without incr... We conducted literature searches in four databases according to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis guideline. We included prospective phase II/III trials of patient... Seven studies were included. All studies had a median follow-up of greater than 4 years. There were heterogeneities in fractionation, treatment planning, and delivery. Studies demonstrated effectivene... There is strong evidence that it is possible to improve oncologic outcomes without substantially increasing toxicity through MR-guided focal boost, at least in the setting of a 35-fraction radiotherap...